Dr. Edward Garon, David Geffen School of Medicine at UCLA, discusses results in a trial that demonstrated a significant survival benefit with nintedanib combined with second line docetaxel in advanced lung adenocarcinoma.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, discusses results in a trial that demonstrated a significant survival benefit with nintedanib combined with second line docetaxel in advanced lung adenocarcinoma.
leggi di più
leggi meno
10 anni fa
#cancergrace, #david, #dr, #edward, #garon, #geffen, #grace, #gracecast, #inhibitor, #medicine, #nintedanib, #of, #school, #ucla, #vegf
